Low-Energy Total Diet Replacement Does Not Worsen Eating Disorder Symptoms in High-Risk Patients: Lancet

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-27 15:30 GMT   |   Update On 2025-06-27 15:30 GMT

Researchers have found in a new study that a 12-week low-energy total diet replacement program did not exacerbate eating disorder symptoms in individuals with overweight or obesity and type 2 diabetes who were at high risk of developing such disorders. The study was conducted by Elena T. and fellow researchers published in The Lancet Psychiatry journal.

Low-calorie TDR diets, usually formula products of nutritionally complete fare like soups, shakes, and bars, are most frequently employed for inducing fast weight loss in those with obesity. Their strict composition and emphasis on weight loss have, however, fueled worry over their capacity to induce disordered eating, particularly in susceptible individuals. That fear was addressed by this trial in a rigorous assessment of the safety and psychological effects of TDR in a high-risk group.

The trial was a randomized, controlled, non-inferiority trial in England involving participants with type 2 diabetes, overweight, and exhibiting signs of eating disorder symptoms. Participants were allocated (1:1) to a low-energy TDR program or standard care for diabetes.

Intervention comprised:

  • 12 weeks of low-energy diet with formula products

  • 8 weeks of stepped reintroduction of foods

  • 4 weeks of weight maintenance advice tailored to participants' preferences

Behavioral treatment was provided remotely. The main outcome was modification in the Eating Disorder Examination Questionnaire (EDE-Q) global score at 6 months. Safety was measured by tracking the development of any new cases of eating disorder. The non-inferiority bound was +1 SD (0.72) for the EDE-Q score.

Participant Profile

  • From March 8 to September 12, 2023, 56 participants were enrolled altogether

  • 28 in intervention group and 28 in control group

  • Mean age: 49.9 years (SD 8.1)

  • Gender: 35 (63%) women, 20 (36%) men, 1 (2%) non-binary

  • Ethnicity: 54 (96%) White, 2 (4%) Asian

  • Mean BMI: 39.6 kg/m² (SD 7.8)

  • Mean baseline EDE-Q score: 3.3 (SD 0.4)

Key Findings

At 6 months, when TDR program concluded:

  • Mean weight loss in the intervention group was –13.9 kg (SD 11.2)

  • Control group lost –3.7 kg (SD 7.9)

  • Between-group difference in weight: –10.2 kg (95% CI: –14.2 to –6.2)

Symptoms of eating disorders improved:

  • Between-group difference in EDE-Q global score: –0.8 points (95% CI: –1.4 to –0.3), establishing non-inferiority

  • No participant was suspected of having a new eating disorder

  • At 12 months, while between-group differences in weight change were no longer statistically significant, EDE-Q score improvement was maintained, suggesting psychological benefit over the long term.

Engagement in a remotely delivered, structured total diet replacement (TDR) program did not exacerbate eating disorder symptoms in individuals with type 2 diabetes and obesity who were at elevated risk for disordered eating. The program resulted in significant weight reduction and even demonstrated evidence of decreasing eating disorder scores. This study justifies the safe implementation of TDR with adjunctive behavioral treatment in clinical practice.

Reference:

Tsompanaki, E., Aveyard, P., Park, R. J., Jebb, S. A., & Koutoukidis, D. A. (2025). An intensive weight loss programme with behavioural support for people with type 2 diabetes at risk of eating disorders in England (ARIADNE): a randomised, controlled, non-inferiority trial. The Lancet. Psychiatry, 12(7), 483–492. https://doi.org/10.1016/S2215-0366(25)00126-9


Tags:    
Article Source : The Lancet Psychiatry

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Medical Bulletin 27/Jun/2025

Health Bulletin 25/June/2025

Medical Bulletin 25/Jun/2025